MSA Trial in early stage <4yrs patients completed. Company is now in trading halt

[Downhillracer]

The trial finished in Nov, the data crunching must be complete, the company has gone into a trading halt, pending revealing topline results. We should know in a day or two. This has a real good chance of success in my opinion. We will know soon enough. I don't own any Alterity (ATH)but think I have MSA.

[Cinnamon40]

Where was this trial based ?

[Downhillracer in reply to Cinnamon40]

It was based in the USA with recruitment centers across the world. , including UK

[Juliehabib in reply to Cinnamon40]

Go on YouTube video titled

Alterity Therapeutics Shareholder Webinar - ATH434-201 Phase 2 clinical study results

Out come seems very positive!

[Downhillracer]

Data is out. It worked. All dose groups slowed progression when compared with the placebo.

[Juliehabib]

go on YouTube the video outcome is titled

Alterity Therapeutics Shareholder Webinar - ATH434-201 Phase 2 clinical study results

Seems a positive outcome

[Cinnamon40]

Thank you for that. Good news! Hopefully they will make it available as soon as possible!

[WTS3]

Do you know if there will be a phase 3 trial or how to get if you have MSA?

[Downhillracer in reply to WTS3]

Right now nothing is certain. Alterity just raised $40Musd so it looks like they are preparing for a P3 trial, but so far there have been no talks announced with the FDA.

The NfL protein results from the spinal fluid are not in yet. That protein is a very reliable indicator of neuron damage. Spinal fluid is the same fluid as in the brain.

They are also talking about a partnership with big pharma to bring this to patients. I hope they get accelerated approval, but right now nobody knows.

[GHG_]

That certainly sounds encouraging. Do you know the name of the company who are carrying out the trials?

[Downhillracer in reply to GHG_]

That would be Alterity GHG. So far they have not announced the phase3. The trial center is based in Vanderbuilt University in Tennessee.

There is a trial for MSA currently recruiting for Lundbeck but recruitment centres only in the USA. Started in Dec 2024. Recruiting 360 patients. That is going after the same target as Alterity, which is clumps of alpha-synuclein that clog up the neurons. Totally different method to Ath434. Lundbecks drug failed to impress in their phase2, but that trial was mainly advanced patients. They did a post hoc study of the earlier stage patients in the P2 trial and claim a 42% improvement. No idea how they calculated that, but the phase 3 is recruiting only patients below 5 years.

A-syn is an essential protein in the neuron, but when the proteins clump is when problems occur. Alterity claim labile(free) Iron caused the clumping. Uncontrolled iron removal by current approved chelators take too much iron and cause serious problems. Ath 434 is a very mild chelator and can only remove free iron. It is a small molecule that can penetrate the membrane of the neuron. A simple pill.

The Lundbeck drug is a large molecule man made protein designed to stick to A-syn clumps and remove them, called a monoclonal antibody. Delivered into the blood by a monthly infusion. It operates outside the neuron. If that 42% reduction turns out to be true, then this trial has a reasonable chance. Lundbeck specialize on neuro drugs. Goes to say they are not fools. I would think if it is also good, with one drug working inside neurons(Ath434) and the Lundbeck MAB(monoclonal antibody) working around the neurons, that may be the 1--2 hit needed to stop this thing. Fingers crossed. In the meantime I hope the FDA give 434 accelerated approval to get it to patients now.